70-80% Reduction In Covaxin Trial Participation: AIIMS

PUBLISHED ON: December 17, 2020 | Duration: 8 min, 45 sec

  
loading..
The results of the first phase trial of Covid vaccine candidate Covaxin, developed by Bharat Biotech, show that the vaccine induced an immune response and did not lead to any serious side-effects, this according to a pre-print study published by Bharat Biotech. This has not been peer-reviewed, which means it hasn't been reviewed by a third party. An AIIMS doctor said that for the third phase of trial of the Bharat Biotech vaccine, there's a 70-80 per cent reduction in those volunteering for the test.
ALSO WATCH
Top News Of The Day: 16,738 Covid Cases In 24 Hours, Highest In 6 Weeks

................................ Advertisement ................................

................................ Advertisement ................................

Listen to the latest songs, only on JioSaavn.com